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Constitutive activation of the chemokine receptor CXCR4 hasbeen associated with tumor progression, invasion, andchemotherapy resistance in different cancer subtypes. Although
the CXCR4 pathway has recently been suggested as an adverse prognos-
tic marker in diffuse large B-cell lymphoma, its biological relevance in
this disease remains underexplored. In a homogeneous set of 52 biopsies
from patients, an antibody-based cytokine array showed that tissue lev-
els of CXCL12 correlated with high microvessel density and bone mar-
row involvement at diagnosis, supporting a role for the CXCL12-CXCR4
axis in disease progression. We then identified the tetra-amine IQS-
01.01RS as a potent inverse agonist of the receptor, preventing CXCL12-
mediated chemotaxis and triggering apoptosis in a panel of 18 cell lines
and primary cultures, with superior mobilizing properties in vivo than
those of the standard agent. IQS-01.01RS activity was associated with
downregulation of p-AKT, p-ERK1/2 and destabilization of MYC, allow-
ing a synergistic interaction with the bromodomain and extra-terminal
domain inhibitor, CPI203. In a xenotransplant model of diffuse large B-
cell lymphoma, the combination of IQS-01.01RS and CPI203 decreased
tumor burden through MYC and p-AKT downregulation, and enhanced
the induction of apoptosis. Thus, our results point out an emerging role
of CXCL12-CXCR4 in the pathogenesis of diffuse large B-cell lym-
phoma and support the simultaneous targeting of CXCR4 and bromod-
omain proteins as a promising, rationale-based strategy for the treatment
of this disease.
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ABSTRACT
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common type of non-Hodgkin lymphoma among adults,
accounting for 30-40% of newly diagnosed cases.1
Although the introduction of rituximab into clinical prac-
tice has increased the survival of affected patients by 10-
15%,2 60% of patients with high-risk DLBCL are still not
cured by immunochemotherapy and have a dismal out-
come. For this subgroup, the development of more effec-
tive salvage strategies remains an important objective.
Gene expression profiling studies have confirmed the
heterogeneity of DLBCL, not otherwise specified, and
have recognized two major subtypes according to the
putative cell of origin, i.e. activated B-cell (ABC) and ger-
minal center B-cell (GCB).3 These studies have also evi-
denced the role of the stromal microenvironment in the
pathogenesis of the disease, as well as in environment-
mediated resistance of DLBCL cells to chemotherapeu-
tics.4 As normal B cells are strongly dependent on soluble
cytokines for their development and throughout their
whole lifespan, it is not surprising that malignant B cells
exploit their microenvironment interaction properties for
their own selective advantage.5 The CXCR4 chemokine
receptor (fusin, CD184) has a well-known function in
normal B-cell development, including homing of
hematopoietic stem cells to the bone marrow, B-cell and
T-cell lymphopoiesis, leukocyte trafficking, and B-cell
positioning in the germinal center, among others.6-11
CXCR4 overexpression has been linked to metastasis in
a variety of cancers and recently identified as an adverse
prognostic factor in DLBCL.12,13 Accordingly, the CXCR4
ligand, CXCL12 (SDF-1α), is among the genes included
in the proangiogenic “stromal 2 gene signature” associat-
ed with an unfavorable outcome in DLBCL.4 This
cytokine is secreted by normal and tumor stroma and is
a major regulator of cell chemotaxis.14 Leukemia stem
cells and other CXCR4-expressing tumors utilize the
CXCL12-CXCR4 signaling axis to localize to vascular
and endosteal niches normally restricted to hematopoiet-
ic stem cells,15 thus obtaining protection from the effects
of cytotoxic chemotherapy and making these niches look
like a reservoir for minimal residual disease and relaps-
es.16-18 CXCR4 expression allows tumor cell migration,
and homing of the neoplastic cells to sites where non-
malignant stromal cells express CXCL12.15 This latter
promotes tumor progression by recruiting CD31+
endothelial progenitor cells and consequent tumor angio-
genesis.19-21 CXCR4 is expressed in hematologic tumors
as diverse as B-cell acute lymphoblastic leukemia, acute
myeloid leukemia, chronic lymphocytic leukemia and
multiple myeloma, and various ongoing clinical trials for
patients with relapsed/refractory hematologic malignan-
cies and recurrent high-grade glioma are evaluating the
benefit of targeting the tumor microenvironment
through CXCL12-CXCR4.22-27
Here we analyzed the clinical significance of CXCL12
expression level in a homogeneous series of patients
with de novo DLBCL. We further characterized a new,
potent CXCR4 inhibitor showing in vitro and in vivo com-
binational activity with a BET bromodomain inhibitor,
thereby demonstrating that dual targeting of CXCR4 and




Fifty-two biopsy specimens from untreated patients with de
novo DLBCL from the Catalan lymphoma-study group (GEL-
CAB) were included in this study (see details in Online
Supplementary Table S1 and the Online Supplementary Materials
and Methods). For functional studies, primary tumor cells from
five patients were isolated, cryopreserved, and conserved within
the hematopathology collection of our institution (Hospital
Clínic-IDIBAPS Biobank R121001-094), as previously
described.28 Primary cultures were maintained in complete medi-
um in the presence of the mesenchymal cell line StromaNKTert
(Riken BioResource Center)29 at a 4:1 ratio, to prevent sponta-
neous ex vivo apoptosis. The ethical approvals for this project,
including informed consent from the patients, were granted fol-
lowing the guidelines of the Hospital Clínic Ethics Committee
(Institutional Review Board, registration number 2012/7498).
Cell lines
Thirteen DLBCL cell lines from both GCB and ABC subtypes
were used in this study. SUDHL-4, SUDHL-6, SUDHL-8,
SUDHL-16, NUDHL-1 and U2932 cell lines were purchased
from the Deutsche Sammlung von Mikroorganismen und Zellkulturen
(DSMZ). SUDHL-2 and WSU-DLCL2 were obtained from the
American Type Culture Collection (ATCC) cell bank (LGC
Standards). OCI-LY8 and Toledo were kindly provided by Dr M.
Raffeld (National Cancer Institute, Bethesda, MD, USA) and Dr
MA Piris (Fundación Jiménez Díaz, Madrid, Spain). OCI-LY3
and OCI-LY10 cells were provided by Dr A. Staiger (Dr.
Margarete Fischer-Bosch Institute of Clinical Pharmacology,
Stuttgart, Germany). HBL-1 was provided by Dr E Valls
(Transcriptional regulation of gene expression group, IDIBAPS,
Barcelona, Spain). Cell lines were authenticated upon reception
by short tandem repeat profiling, using an AmpFlSTR identifier
kit (Thermo Fisher Scientific), and based on available short tan-
dem repeat profiles. All cell lines were cultured routinely at 37ºC
in a humidified atmosphere with 5% carbon dioxide in RPMI
1640 or Iscove modified Dulbecco medium supplemented with
10% to 20% heat-inactivated fetal bovine serum, 2 mM gluta-
mine and 50 mg/mL penicillin-streptomycin (Thermo Fisher).
Mycoplasm infection was routinely tested for by polymerase
chain reaction. SUDHL-6 cells expressing green fluorescent pro-
tein (GFP) and Luciferase reporter genes, were generated as pre-
viously reported.30
Immunohistochemistry
Fifty-two DLBCL samples were included in tissue microarrays
using duplicated cores of 1 mm per tumor sample. CD31+
microvascular density was stained and quantified as previously
described.31 Microvascular density values were grouped in quar-
tiles and considered high or low when above or below the 50th
percentile. Xenograft tumor samples were stained for phospho-
histone H3, cleaved caspase-3 and MYC, as previously
described.32 Phospho-Akt was detected using a monoclonal anti-
phospho-Akt-Ser473 antibody (Cell Signaling Technology).
Preparations were evaluated on a DP70 or a BX51 microscope
using Cell B Basic Imaging Software (Olympus).
Western blot analysis
Whole cell proteins were extracted from 107 DLBCL cells as
previously described.28 Proteins (30-50 mg/lane) were subjected
to 10-12% sodium dodecylsulfate-polyacrylamide gel elec-
trophoresis, and transferred onto polyvinylidene difluoride
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membranes (Immobilon-P; Millipore), or nitrocellulose mem-
branes (Amersham Biosciences). Membranes were then incubat-
ed with primary and secondary antibodies (Online Supplementary
Materials and Methods) and visualized on a mini-LAS4000 device
(Fujifilm) by enhanced chemiluminescence (ECL, Amersham
Life Science).
Flow cytometry analysis
For the detection of surface CXCR4, DLBCL cells (2x105) were
stained with a phycoerythrin (PE)-labeled anti-CXCR4 or iso-
type control antibody (BD Biosciences). For the CXCR4 occu-
pancy assay, cells were pretreated for 1 h with IQS-01.01,
AMD3100 (Sigma-Aldrich) or an anti-human CXCR4 control
antibody, followed by sCXCR4 staining as above. For quantifi-
cation of apoptosis, cells were labeled with Pacific Blue-conju-
gated annexin V (Thermo Fisher). A total of 10,000 events were
acquired and analyzed on an Attune acoustic focusing cytometer
(Thermo Fisher). The mean fluorescence intensity ratio was cal-
culated as the ratio between the median fluorescence intensity
of the CXCR4-labeled sample and that of the isotype.
Chemotaxis assay
DLBCL cells (5x106 cells/mL) were cultured for 1 h in culture
medium not containing fetal bovine serum but supplemented
with 0.5% bovine serum albumin (Sigma-Aldrich), in the pres-
ence or absence of 100 mM AMD3100 or IQS-01.01RS, and ana-
lyzed for CXCL12-dependent chemotaxis, as previously
described.28 Values are referred to cells cultured without
CXCL12.
Cell proliferation assay
DLBCL primary cultures and cell lines (5x104 cells) were incu-
bated for 24-48 h with IQS-01.01RS, AMD3100 and/or CPI203
(kindly provided by Constellation Pharmaceuticals) at the indi-
cated doses. MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenylte-
trazolium bromide) reagent (Sigma-Aldrich) was added for 1–5
additional hours before spectrophotometric measurements.
Each measurement was made in triplicate. Values are represent-
ed using untreated control cells as the reference. Combination
indexes were calculated using Calcusyn software version 2.0
(Biosoft). The interaction between two drugs was considered
synergistic when the combination index was less than 0.8.
In vivo assays
Prior to efficacy testing, an acute toxicity assay was conducted
in NSG mice exposed to IQS-01.01RS salt or AMD3100.
Animals (2 adult males and 2 adult females per dose) received a
single administration of vehicle, IQS01.01-RS (per os) or plerix-
afor (intraperitoneally) at doses ranging from 2 to 10 mg/kg, and
were monitored during the first 4 h after administration, and
daily for 2 weeks, for viability/mortality and vital parameters.
This toxicity assay defined a maximum non-lethal dose of 5
mg/kg for AMD3100, while the maximum lethal dose of IQS-
01.01RS remained unreached.
For the systemic DLBCL model, 8-week old NSG female mice
(n=12) were inoculated intravenously with 107 SUDHL6-GFP-
Luc cells, randomly assigned into three equivalent cohorts, and
treated daily with 5 mg/kg AMD3100 (intraperitoneally), 10
mg/kg IQS-01.01RS salt (per os) or vehicle. After 27 days, ani-
mals were sacrificed and peripheral blood was collected by sub-
mandibular puncture. Erythrocytes were lysed using ACK buffer
(Quality Biological) and the percentage of SUDHL-6 cells was
evaluated by detection of a GFP signal on an Attune cytometer.
For the subcutaneous DLBCL model, SUDHL6-GFP-Luc cells
were inoculated subcutaneously in 8-week old NSG female mice
as previously.28,32 Animals were randomly assigned into four
cohorts of four mice each and were given a twice daily dose of
1.5 mg/kg CPI203 (intraperitoneally), a daily dose of 2 mg/kg
IQS-01.01RS (per os), both agents, or an equal volume of vehicle.
Tumor engraftment was determined weekly following mice
injection with 75 mg/kg D-luciferine (AnaSpec) and biolumines-
cence imaging (BLI) using an Aequoria Luxiflux device equipped
with an ORCA-ER camera (Hamamatsu). The bioluminescence
imaging signal was quantified using Image J software. Tumor
volume was measured by external calipers twice a week, up to
28 days. Animals were then sacrificed and tumors were harvest-
ed and weighed. Animals were handled following protocols
approved by the Animal Ethics Committee of the University of
Barcelona (protocol #154/16).
Statistical analysis
A Wilcoxon rank-sum test, Fisher exact test, Spearman rank
correlation or t-test was used to examine the statistical signifi-
cance of associations between clinico-pathological data and
CXCL12-CXCR4 positivity or cytokine expression level, as
appropriate. Survival curves were estimated using the Kaplan-
Meier method. A log-rank test was used to compare survival
curves between groups. For in vitro and in vivo functional assays,
unpaired and paired t-tests were employed to obtain the statisti-
cal significance. The Benajmini-Hochberg method was used to
adjust P-values for multiple testing. Results were considered sta-
tistically significant when the P value was less than 0.05.
Results
CXCL12 expression correlates with microvascular 
density and confers an  unfavorable prognosis 
to patients with diffuse large B-cell lymphoma
Gene expression profiling studies have highlighted the
prognostic value of the microenvironment and compo-
nents of several immune regulatory pathways in DLBCL.4
To characterize which cytokines may have a significant
impact on the pathogenesis of DLBCL, we performed a
fluorescence-based cytokine antibody array using frozen
tissue from 12 DLBCL cases, out of an initial cohort of 52
patients (Online Supplementary Table S1), and correlated
expression data with clinico-biological characteristics of
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Table 1. Top cytokines associated with high microvessel density in diffuse large B-cell lymphoma biopsies.
Cytokine Mean Mean Difference t statistic P Adjusted P
(MVD=low) (MVD=high)
SDF1α/CXCL12 5.207 5.637 0.430 -3.758 0.000 0.032
IGFBP2 4.467 4.946 0.479 -3.744 0.000 0.032
IGFBP1 5.085 5.601 0.516 -3.666 0.001 0.032
MVD: microvessel density.
the patients. Among the 175 cytokines included in this
array, we found that only CXCL12, IGFBP2 and IGFBP3
correlated significantly with high microvascular density
(P<0.05) (Table 1), a parameter associated with an unfa-
vorable prognosis in DLBCL.31,33 Additionally, high
expression of CXCL12 correlated significantly with bone
marrow involvement at diagnosis (P=0.02, data not
shown), thus supporting a role for the CXCL12-CXCR4
axis in the progression of DLBCL.
IQS-01.01RS is a novel CXCR4 inhibitor with improved
pharmacological properties
To evaluate the therapeutic potential of targeting
CXCR4 in DLBCL, we took advantage of a novel family
of CXCR4 inhibitors with improved pharmacodynamic
properties and lower cardiotoxicity than the standard
CXCR4 inhibitor AMD3100.34,35 Similarly to AMD3100,
IQS-01.01 is a symmetric molecule with a central p-
phenylene group harboring two chiral carbons. The com-
pound thus comports three stereoisomers, namely IQS-
01.01RR, IQS-01.01SS and IQS-01.01RS (Figure 1A).
Nitrogen atoms on each site are intercalated in carbon
chains at a similar distance as those of the cyclam in
AMD3100 providing IQS-01.01 with positively charged
nitrogen atoms at physiological pH which, as with
AMD3100, will interact with the lateral chains of acidic
amino acids of CXCR4, but with greater flexibility. We
first assessed the inhibitory activity of IQS-01.01 (racemic
mixture), and its three individually purified stereoiso-
mers, using a CXCR4 antagonist screening study.
AMD3100 was used as a reference drug. As shown in
Figure 1B, the three stereoisomers had superior CXCR4
antagonist activity to that of AMD3100, with IQS-
01.01RS (see structure in Figure 1C) being the most
potent agent. This compound led to a 181% inhibition of
receptor activity, thus resembling an inverse receptor ago-
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Figure 1. Design of a new potent inhibitor of CXCR4. (A) Skeletal structure of IQS-01.01. *chiral carbons. (B) Inhibition of CXCL12-mediated intracellular cAMP
release was determined in the presence of a racemic mixture of IQS-01.01 and its three individually purified stereoisomers, using AMD3100 blocking activity as a
reference control. (C) Ball-and-stick representation of IQS-01.01RS. * chiral carbons. (D) MTT assay showing superior antitumor effect of IQS-01.01RS compared to
that of the IQS-01.01 racemic mixture after 48 h. The graph shows mean values obtained from three GCB-DLBCL cell lines (SUDHL6, SUDHL-16, and WSU-DLCL2)
and three ABC-DLBCL cell lines (OCI-LY3, OCI-LY10 and SUDHL-2). (E) Inhibition of CXCL12-induced migration upon DLBCL cell treatment with a 100 mM dose of IQS-
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Figure 2. IQS-01.01RS has better pharmacological properties than those of AMD3100. (A) Predicted docking of IQS-01.01RS (red) and AMD3100 (blue) on their
target, CXCR4 (orange). CXCL12 is represented in green. (B) A CXCR4 occupancy assay shows the competition between IQS-01.01RS or AMD3100 (100 mM) with a
phycoerythrin-labeled anti-CXCR4 antibody for binding to the receptor. A blocking antibody (30 mg/mL, R&D Systems) was used as a control. (C) Inhibition of CXCL12-
induced migration upon DLBCL cell treatment with increasing doses of IQS-01.01RS or AMD3100. The graphs show mean values from three GCB-DLBCL cell lines
(SUDHL8, Toledo and SUDHL-6) and two ABC-DLBCL cell lines (U2932 and OCI-LY3). Data are representative of at least three independent experiments. (D) Mean
percentage of tumor B cells detected in blood samples of NSG mice injected intravenously with SUDHL-6-GFP-LUC cells and treated for 27 days with IQS-01.01RS,
AMD3100, or vehicle (n=4 animals/group). (E) Time-dependent antitumor effect of IQS-01.01RS (100 mM) and AMD3100 (100 mM) in a panel of 13 DLBCL cell lines;
the effect was determined by a MTT assay. Representative results from three experiments are shown. (F) Relative induction of apoptosis in CD19+ tumor B cells upon
treatment of primary DLBCL biopsies (n=5) with the indicated doses of IQS-01.01RS for 48 h. The mean viability of untreated primary cells was 79±8%. (G) Western
blot analysis of CXCR4 downstream signaling in SUDHL6 and U2932 cells upon 2 h starvation, followed by exposure to recombinant CXCL12 for 1 min, with or without
pretreatment with the indicated doses of IQS-01.01RS or AMD3100. β-actin was used as a loading control. (H) CXCR4 downstream signaling and MYC modulation
in SUDHL-6 cells at different time points, after 2 h starvation followed by receptor triggering in the presence or absence of 100 mM IQS-01.01RS. β-actin was used





nist. We then analyzed the antitumor activity of this
highly active stereoisomer, together with IQS-01.01
(racemic mixture) in six representative DLBCL cell lines
of both GCB and ABC subtypes. As shown in Figure 1D,
IQS-01.01RS was significantly more active than the
racemic mixture at all the doses tested, with the greatest
effect being observed at the 100 mM dose (mean cytotox-
icity: 44%; range, 42-49%). This effect was mainly attrib-
uted to proliferation blockade, as IQS-01.01RS-treated
cultures showed low (< 5%) levels of apoptosis (data not
shown). In agreement with this, migration experiments
using a CXCL12 gradient further demonstrated that IQS-
01.01RS was a more potent inhibitor of cell chemotaxis
than was the racemic mixture, with a 2-fold improve-
ment of cell migration blockade (Figure 1E). Based on
these results, we proceeded to a deeper study of the
stereoisomer of choice, IQS-01-01RS.
A predictive docking model showed that this stereoiso-
mer localized into the extracellular CXCL12 binding
domain of CXCR4, close to the position occupied by
AMD3100, and simultaneously interacted with an inner,
transmembrane domain of the receptor. This unique fea-
ture potentially provides IQS-01.01RS with the ability to
inhibit CXCR4 in the presence of the ligand, and to inter-
fere with the catalytic activity of the receptor (Figure 2A).
Supporting this model, using the representative cell line
SUDHL-6 we observed that IQS-01.01RS and AMD3100
had similar CXCR4 occupancy activity (Figure 2B), and
had similar anti-migratory properties against a CXCL12
gradient in vitro, both in ABC- and GCB-DLBCL cell lines
(Figure 2C). However, IQS-01.01RS triggered superior
mobilization of DLBCL cells into the circulating blood of
the animals (Figure 2D) and was able to block the prolif-
eration of a panel of 13 GCB/ABC-DLBCL cell lines in a
time-dependent manner, contrasting with the modest
antitumor activity of AMD3100 (40% versus 12% mean
cell growth inhibition at 48 h) (Figure 2E and Table 2). In
addition, in a set of five DLBCL primary cultures, a dose-
dependent induction of apoptosis was observed upon
exposure to IQS-01.01RS (Figure 2F), contrasting with the
reported inability of AMD3100 to induce cell death.36
Accordingly, the analysis of CXCR4 downstream signal-
ing showed that the capacity of IQS-01.01RS to inhibit
basal and CXCL12-induced phosphorylation of ERK1/2,
AKT and the AKT downstream kinase GSK3-β, was
superior to that of AMD3100 (Figure 2G). Of special
interest, IQS-01.01RS, rather than AMD3100, allowed
strong downregulation of the MYC proto-oncogene in
ABC- and GCB-DLBCL cells (Figure 2H). This down-
stream target of CXCR4 with a well-established role in
the progression of DLBCL,37 has been reported to depend
on AKT phosphorylation level for its stabilization, medi-
ated by a GSK3-β-dependent phosphorylation of its
Thr58 residue and consequent proteosomal degrada-
tion.38,39 Supporting the hypothesis that the downregula-
tion of MYC may be consequent to inhibition of the
CXCR4-AKT axis in IQS-01.01RS-treated cells, the
expression of both p-AKT and MYC was almost com-
pletely abrogated within a few minutes after the addition
of IQS-01.01RS (Figure 2H) and this phenomenon could
be maintained for at least 3 h (data not shown).
Collectively, these results indicate that the new CXCR4
inhibitor IQS-01.01RS has a unique structure that enables
its binding to two distinct domains of the receptor, con-
ferring improved mobilizing properties in vivo, as well as
superior antitumor activity in vitro.
IQS-01.01RS cooperates with BET bromodomain
inhibition in vitro and in vivo
Based on our observation that IQS-01.01RS had the
capacity to downregulate MYC, we further investigated
in our 13 DLBCL cell lines whether the compound could
cooperate with the BET bromodomain antagonist
CPI20332 to block cell proliferation. The combination of
each agent induced up to 78% cytoxicity at the optimal
doses of 100 mM IQS-01.01RS and 500 nM CPI203, with
a mean CI of 0.67, indicative of a synergistic drug interac-
tion in both ABC- and GCB-DLBCL cells (Figure 3A and
Table 2). As expected, a dramatic reduction in MYC pro-
tein levels was observed after exposure to the combina-
tion (Figure 3B). We confirmed by quantitative poly-
merase chain reaction analysis and cycloheximide protein
stability assays that this phenomenon was consequent to
a simultaneous CPI203-evoked transcriptional repression
of MYC gene and an IQS-01.01RS-mediated destabiliza-
tion of MYC protein (Figure 3C,D). Confirming that this
effect was not due to a BRD4 inhibitor-mediated dimin-
ished production of CXCR4, as previously described in T
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Table 2. Sensitivity of diffuse large B-cell lymphoma cell lines to CXCR4 and BET bromodomain inhibition.
CXCR4 expression IQS-01.01RS CPI203 Combination
(MFI-R) cytotoxic effect cytotoxic effect index
Subtype Cell line (100 µM) (0.5 µM)
OCI-LY8 36 32% 38% 1.1
SUDHL-4 25 37% 59% 0.6
SUDHL-6 41 42% 47% 0.4
GCB SUDHL-16 1 36% 86% 0.5
WSU-DLCL2 3 35% 55% 0.4
Toledo 52 9% 43% 0.5
SUDHL-8 91 38% 14% 1.1
NUDHL-1 1 36% 60% 0.8
                                               OCI-LY3                                   4                                           48%                                           75%                                              0.7
ABC                                     OCI-LY10                                  1                                           40%                                           40%                                              0.8
                                              SUDHL-2                                  1                                           53%                                           95%                                              0.8
                                                 U2932                                    46                                          43%                                           31%                                              0.9
                                                HBL-1                                     1                                           63%                                           39%                                              0.6
ABC: activated B-cell; GCB: germinal center B-cell; MFI-R: median fluorescence intensity ratio.
lymphocytes following JQ1 treatment,40 Figure 3B shows
that CPI203 addition did not alter CXCR4 protein levels
either in the presence or absence of IQS-01.01RS. Flow
cytometry analysis further confirmed that surface levels
of CXCR4 were unmodified by BET bromodomain inhi-
bition (data not shown). To further ascertain the role of
CXCR4 expression in this drug interaction, we estab-
lished genetic depletion of CXCR4 in SUDHL-6 cells
employing a CRISPR/Cas9 gene editing tool to generate
CXCR4 knocked out (KO) cell lines, prior to treatment
with CPI203, IQS-01.01RS and the combination of both
agents. In parallel, and as a control of non-lymphomatous
B malignancy, we used the recently described NALM6-
CXCR4-KO cell line (kindly provided by Dr Jan Burger,
Department of Leukemia, The University of Texas MD
Anderson Cancer Center, Houston, TX, USA). As shown
in Online Supplementary Figure S1, CXCR4-KO cell lines
completely lack CXCR4 molecules on their surface. The
main difference between these two cell lines was the
response to CPI203 as a single agent, which was substan-
tially weaker in NALM6-CXCR4-KO cells. This may
illustrate the recent finding that, in acute myeloid
leukemia cells, CXCR4 signaling is involved in the regula-
tion of MYC transcription mediated by the downregula-
tion of the miRNA let-7a,41 while in DLBCL cells no vari-
ation in MYC mRNA levels are observed following
CXCR4 ligation (Online Supplementary Figure S2). Another
explanation may come from the lower membrane expres-
sion (about one log10) of the receptor observed in parental
acute myeloid leukemia cells when compared to parental
DLBCL cells, suggesting that NALM6 cells are less
dependent on CXCR4 and less susceptible to CXCR4-
dependent cellular stress than are SUDHL-6 cells. Most
importantly, in the acute myeloid leukemia cell line the
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Figure 3. IQS-01.01RS synergizes with the BET bromodomain inhibitor CPI203 in vitro. (A) The relative antitumor effect of IQS-01.01RS (100 mM), CPI203 (0.5 mM)
and the combination of both was determined by a MTT assay, after 48 h. The data shown are the mean results of the 13 DLBCL cell lines. (B) Cooperation between
IQS-01.01RS and CPI203 in the inhibition of CXCR4 downstream signaling, as assessed by western blot analysis of p-AKT and MYC. SUDHL-6 and U2932 cells were
starved for 2 h, and treated for 1 h with 100 mM IQS-01.01RS and/or CPI203 (0.5 mM) prior to a 1 min stimulation with 200 ng/mL recombinant CXCL12. α-tubulin
was used as a loading control. (C) Relative MYC transcript levels in SUDHL-6 and U2932 cells upon 6 h treatment with 100 mM IQS-01.01RS, 0.5 mM CPI203 and
the combination of both. Control untreated cells were used as a reference. (D) Time-dependent determination of MYC protein levels in SUDHL-6 cells treated with
the translational blocker cycloheximide, as previously described,62 in the presence or absence of 100 mM IQS01.01-RS. β-actin was used as a loading control. CI:
combination index; CHX: cycloheximide; COMBO: combination treatment with IQS-01.01RS and CPI203.
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loss of CXCR4 was associated with 30% and 24%
decreases in the cytotoxic effect of CPI203 and the
CPI203/IQS-01.01RS combination, respectively, confirm-
ing that CXCR4 expression was required for the activity
of the bromodomain inhibitor alone, as well as for its
synergistic activity with IQS-01.01RS. In the case of
SUDHL6, although the combination was still active in
CXCR4-depleted cells, the loss of the receptor induced a
13% reduction in the synergistic activity of the two
agents when compared with the parental CXCR4+ cells.
Thus, these results strongly support a crucial role for
CXCR4 in the cooperation between CPI203 and IQS-
01.01RS in malignant B cells.
To assess the efficacy of the drug combination in vivo,
NSG mice were subcutaneously injected with SUDHL6-
GFP-Luc cells, and given IQS-01.01RS, CPI203, the com-
bination of both agents, or the equivalent volume of vehi-
cle, for 13 days. Tumor burden was evaluated weekly by
bioluminescence signal recording and twice a week by
external calipers. At the final time point, tumors were
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Figure 4. IQS-01.01RS and CPI203 cooperate to reduce tumor growth in a subcutaneous mouse model of diffuse large B-cell lymphoma. NSG mice were subcuta-
neously injected with SUDHL6-GFP+Luc+ cells and tumor-bearing mice were randomly assigned to one of the following treatment arms (4 mice per group): IQS-
01.01RS 2 mg/kg daily (per os), CPI203 1.5 mg/kg BID (intraperitoneally), both agents or equal volume of vehicle, for 2 weeks. (A) Tumor volume was evaluated
twice a week using external calipers. (B) Tumor burden was evaluated at week 3 and week 4 by analysis of the bioluminescence signal. Left panel: color maps of
two representative animals per group. Right panel: quantification of luciferase activity using Image J software. (C) Mean tumor weight in each treatment group at
the final time point. (D) Immunohistochemical labeling of p-histone H3, activated caspase-3, MYC and p-AKT in consecutive tissue sections from four representative
tumor specimens (magnification x200). act casp3: activated caspase 3; COMBO/combo: combination treatment with IQS-01.01RS and CPI203; SEM: standard error




extracted and weighed. Figure 4A shows that CPI203 and
IQS-01.01RS as single agents induced 27% and 4% reduc-
tions in tumor growth, respectively, while the combina-
tion of both drugs induced a 38% decrease in tumor bur-
den. Accordingly, reduced luciferase activity as well as a
significant (38%) decrease in tumor weight was detected
in mice given combination treatment compared to the
values in the group administered the vehicle (Figure
4B,C). Histological analysis of the corresponding tumors
confirmed a greater reduction of the mitotic index togeth-
er with an accumulation of apoptotic cells by the combi-
nation therapy, as assessed by phospho-histone H3 and
activated-caspase-3 staining (Figure 4D). In agreement
with the in vitro results, greater reductions in MYC and
phospho-Akt were observed in animals treated with the
combination of drugs (Figure 5D). Collectively, these
results suggest that the combination of IQS-01.01RS with
the BET inhibitor CPI203 enhances the antitumor proper-
ties of each single agent through the blockade of CXCR4
signaling, followed by the abrogation of MYC expression
and the induction of apoptosis.
Discussion 
The chemokine receptor CXCR4 has a prominent role
in homing and retention of tumor cells in their microen-
vironment, and in the promotion of drug resistance.42 It
has been previously reported that CXCR4/CXCL12
expression by tumor cells confers an adverse prognosis to
DLBCL patients.12,43 In agreement with this, we observed
that CXCL12 expression in tumor biopsies correlated
with bone marrow involvement at diagnosis, as well as
highly vascularized tumors. These observations support
the hypothesis that the CXCL12-CXCR4 axis may play a
significant role in neo-angiogenesis in the DLBCL
microenvironment. Accordingly, various reports have
highlighted a correlation between CXCR4 expression and
high serum levels of VEGF in different cancer sub-
types.19,21,44 CXCL12 is also one of the genes included in
the DLBCL pro-angiogenic and unfavorable “stromal-2
signature”,4 while activation of the CXCL12-CXCR4 axis
is related to tumor angiogenesis and recruitment of
endothelial progenitor cells to tumors in myelodysplastic
syndrome, glioma and pancreatic cancer.20,45,46
The CXCL12-CXCR4 axis may, therefore, represent a
new therapeutic target for DLBCL, as inhibition of
CXCR4 and tumor cell mobilization is bound to increase
the accessibility of these lymphomas to anticancer thera-
pies. Validating this strategy, the Food and Drug
Administration-approved drug AMD3100 has been
shown to potentiate the tumor growth inhibition afford-
ed by standard chemotherapeutics and/or irradiation in
preclinical models of glioblastoma,26,47 to inhibit the
engraftment of B-cell acute lymphoblastic leukemia,48 to
mobilize and sensitize acute promyelocytic leukemia
cells to cytosine arabinoside,49 and to enhance the
response to rituximab and to the anti-CD52 monoclonal
antibody alemtuzumab in a mouse model of disseminat-
ed lymphoma.50 In the clinical setting, encouraging pre-
liminary data have been obtained from a phase II study
using AMD3100 and standard chemotherapy in patients
with acute myeloid leukemia.51 In DLBCL, pharmacolog-
ical inhibition of CXCR4 by AMD3100 impairs the prop-
agation of tumor B cells in a systemic mouse model of the
disease.12 Nonetheless, AMD3100 presents serious limita-
tions that could preclude its use as an anticancer drug,
such as some degree of cardiotoxicity and adverse phar-
macodynamic properties including a positive charge at
physiological pH and a limited half-life, impairing its oral
bioavailability.52 Thus, the lack of a CXCR4 inhibitor suit-
able for administration in a standard regimen supports
the development of less toxic and more stable CXCR4-
targeting agents.53
Here, we describe the biological activity of IQS-
01.01RS, a new potential CXCR4 inhibitor with a higher
lethal dose in vivo and better pharmacodynamic proper-
ties than AMD3100.35 We report that by interacting with
a different CXCR4 domain than that with which
AMD3100 interacts, this IQS-01.01RS acts as a putative
allosteric CXCR4 inhibitor, impeding the activation of
the receptor upon CXCL12 ligation and allowing a more
sustained inhibition of the pathway. In vivo, this effect,
together with better pharmacokinetic properties, was
linked to an improved capacity of the compound to
mobilize DLBCL cells. Furthermore, we show that IQS-
01.01RS-mediated blockade of CXCR4 signaling led to
the post-transcriptional downregulation of MYC.
Overexpression of this oncogene is associated with
shorter survival in DLBCL patients,54 and is known to be
stabilized by CXCR4 in cancer cells.55 MYC was consid-
ered to be an undruggable factor until (+)-JQ1, a highly
potent, selective and cell-permeable inhibitor of BRD4, a
member of the BET family of chromatin adaptors, was
first shown to have antitumor activity in multiple myelo-
ma xenograft models.56 Further studies with (+)-JQ1 and
CPI203, a molecule characterized by a superior bioavail-
ability after oral or intraperitoneal administration,32,57
have validated BET bromodomain targeting and subse-
quent blockade of MYC, NF-kB or BCL-2 protein family
signaling as a promising therapeutic strategy in different
subtypes of aggressive B-cell lymphoma, including
DLBCL.58-60 BRD4 is a global regulator of gene transcrip-
tion which selectively recognizes and binds to acetylated
lysine residues in histones to activate transcription and
mitosis. In DLBCL it preferentially localizes in super-
enhancers associated with key transcription factors
implicated in lymphomagenesis, such as MYC, which
are specifically sensitive to BRD4 inhibition thus explain-
ing the selective anti-tumor effect of BRD4 inhibitors.61 It
is worth pointing out that BET bromodomain inhibition,
as a consequence, downregulates other tumor-related
genes apart from MYC.61 Nevertheless, in this work, we
focused on the capacity of CPI203 to inhibit MYC, con-
firming that ABC- and GCB-DLBCL cells are highly sen-
sitive to CPI203 monotherapy, and that the transcription-
al downregulation of MYC achieved by this compound
allows almost complete abrogation of the protein when
the compound is combined with IQS-01.01RS. This dual
approach underlies the synergistic interaction of the two
compounds and consequent sensitization to apoptosis in
vitro and in vivo.
In conclusion, the present work shows that, besides
CXCR4, the level of CXCL12 may also have an impact on
the progression of DLBCL, and describes a new potent
orally available CXCR4 inhibitor with antitumor proper-
ties. In addition, this study offers the first rational basis
for the potential clinical evaluation of a dual approach
combining BET bromodain inhibition and CXCR4 block-
ade in DLBCL.
C. Recasens-Zorzo et al.
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